Results 11 to 20 of about 342 (145)

Nemolizumab for atopic dermatitis

Drugs of Today, 2022
Atopic dermatitis (AD) is a common inflammatory skin disease that has emerging treatments targeting the underlying immunological mechanism. Interleukin-31 (IL-31) is associated with the pathobiological mechanism of AD, contributing to symptoms such as dermatitis and pruritus.
Angelina, Labib, Ashley, Vander Does, Gil, Yosipovitch   +2 more
openaire   +3 more sources

Nemolizumab: First Approval

Drugs, 2022
Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin diseases, including atopic dermatitis (AD), AD associated pruritus (ADaP), prurigo nodularis (PN), chronic
Susan Keam (4873372)
openaire   +3 more sources

24-week real world outcomes of nemolizumab in patients with prurigo nodularis

Journal of Dermatological Treatment
Backgrounds Prurigo nodularis (PN) is a chronic pruritic inflammatory disease associated with immune and neural dysregulation. Although nemolizumab has demonstrated efficacy in clinical trials, real-world post-marketing data remain limited.Objective To ...
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
doaj   +2 more sources

Cutaneous Adverse Events Following Nemolizumab Administration: A Review

Journal of Clinical Medicine
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by epidermal barrier dysfunction and immune dysregulation, with interleukin (IL)-4, IL-13, and IL-31 recognized as key mediators. Prurigo nodularis (PN) is another chronic inflammatory disorder driven by T helper type 2-mediated inflammation and neural dysregulation, leading to
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
openaire   +3 more sources

Resolution of Lichen Simplex Chronicus With Nemolizumab: A Case Report

Journal of Drugs in Dermatology
Lichen simplex chronicus is a debilitating condition characterized by lichenified skin secondary to intractable itch. Lichen simplex chronicus is challenging to treat, with current treatment options, such as topical calcineurin inhibitors, gabapentinoids, and dupilumab, commonly being ineffective, leaving patients with worsening symptoms and poor ...
Fiona S, Gruzmark, Gil, Yosipovitch, Hadar A, Lev-Tov   +2 more
openaire   +3 more sources

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies [PDF]

, 2022
BACKGROUND: Interleukin (IL)‐31 affects the inflammatory response, is involved in epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus.
Komazaki, H., Kawashima, M., Matsumura, T., Kabashima, K.   +3 more
core   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab [PDF]

, 2023
BACKGROUND: Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk.
Johann E. Gudjonsson, J. Michelle Kahlenberg, Nakamura, Mio, Julia, Valerie, Matthew T. Patrick, Van Delm, Wouter, Feiyang Ma, Paul Harms, Mehrnaz Gharaee-Kermani, Harms, Paul, Grace Hile, Gudjonsson, Johann E, Olesya Plazyo, Mio Nakamura, Ma, Feiyang, Tsoi, Lam C, Lazzari, Anne, Billi, Allison C, Gharaee-Kermani, Mehrnaz, Allison C. Billi, Modlin, Robert L, Chaskar, Prasad, Plazyo, Olesya, Anne Lazzari, Christophe Piketty, Xing, Xianying, Wouter Van Delm, Lam C. Tsoi, Krishnaswamy, Jayendra Kumar, Xianying Xing, Emanual Maverakis, Robert L. Modlin, Piketty, Christophe, Prasad Chaskar, Patrick, Matthew T, Valerie Julia, Maverakis, Emanual, Hile, Grace, Kahlenberg, J Michelle, Jayendra Kumar Krishnaswamy   +39 more
core   +1 more source

Acquired reactive perforating collagenosis treated with nemolizumab

JAAD Case Reports
Shehani T. Perera, BS, Sofia Vescovacci, BS, Sara Kaye Givens, PA, Marc Inglese, MD, András Schaffer, MD, PhD, Austinn Miller, MD   +5 more
doaj   +4 more sources

Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab [PDF]

Journal of Allergy and Clinical Immunology, 2022
Prurigo nodularis (PN) is a debilitating, difficult-to-treat, intensely pruritic, chronic inflammatory skin disease characterized by hyperkeratotic skin nodules. The pathogenesis of PN is not well understood but is believed to involve cross talk between sensory nerve fibers, immune cells, and the epidermis.
Lam C, Tsoi, Feriel, Hacini-Rachinel, Paul, Fogel, Francois, Rousseau, Xianying, Xing, Matthew T, Patrick, Allison C, Billi, Celine C, Berthier, J Michelle, Kahlenberg, Anne, Lazzari, Henning, Wiegmann, Sonja, Ständer, Christophe, Piketty, Valerie, Julia, Jayendra Kumar, Krishnaswamy, Johann E, Gudjonsson   +15 more
openaire   +2 more sources